Kornimate/medical-research-clean huggingface dataset:
effectiveness of melissa officinalis for the treatment of probable sleep bruxism in children and adolescents

Conditions: Sleep Bruxism; Adolescent; Children; Temporomandibular Joint Disorders

Summary: objective: to investigate, through a controlled and randomized clinical trial, the effectiveness of using melissa officinalis in different concentrations in the treatment of children and adolescents with probable sleep bruxism. methodology: this is a randomized, triple-blind, crossover, and placebo-controlled clinical trial. the research participants will be children aged 5 to 10 years old and adolescents aged 11 to 16 years old who attend dental treatment at the fo/ufrj pediatric dentistry clinics. after approval by the human research ethics committee, children and adolescents will undergo homeopathic treatment with melissa officinalis in different concentrations for possible sleep bruxism. in addition, research participants will undergo an assessment of tmj, sleep, circadian cycle, quality of life, and quality of life related to oral health. the data will be tabulated and analyzed according to sex, age group, presence of possible sleep bruxism, presence or absence of tmd, circadian characteristics, presence or absence of sleep disorders, daytime and nighttime behavioral characteristics. the data will be tabulated and evaluated using spss 21.0. absolute and relative frequency, odds ratio, correlation analysis and other relevant analyzes and statistical tests (p\<0.05) will be carried out in accordance with the objectives proposed by the study


Eligibility criteria:
inclusion criteria: * patients aged 5 to 16 years; * patients with complete primary dentition, mixed or secondary dentition; * patients with probable sleep bruxism. exclusion criteria: * patients with special needs (psychological, psychiatric and neurological, diagnosed with anxiety disorder or any systemic impairment); * patients with parafunctional habits (finger sucking and/or pacifier, onychophagia, biting objects, etc.) * patients with caries lesions in dentin in one or more elements (icdas values 4, 5 and 6); * patients affected by molar-incisor hypomineralization (mih) * patients with dental anomalies such as dentinogenesis imperfecta, amelogenesis imperfecta, dysplasia dentin, hypoplasia, and enamel hypocalcification; * patients with severe malocclusions: class ii and iii or crossbite and open bite type; * patients using orthodontic appliances; * patients who are taking medications for anxiety disorders or any other that cause alterations in the central nervous system or that alter salivary flow.

Keywords: sleep bruxism homeopathy adolescent children
copeptin during a standardized psychological stress test

Conditions: Stress

Summary: the aim of the psyco study is to determine whether psychological stress has an influence on copeptin levels.

healthy volunteers undergo the tsst and stress hormones as cortisol and copeptin are measured

Eligibility criteria:
inclusion criteria: •aged over 18 years exclusion criteria: * intake of any kind of medication (except birth control pill) * bmi \>30 kg/m2 * evidence of any acute illness * history of chronic illness * baseline glucose level \>7 mmol/l baseline sodium level \ 145 mmol/l

Keywords: copeptin psychological stress the trier social stress test (tsst)
the effect of bilateral infraorbital+ infratrochlear nerve block for rhinoplasty operations

Conditions: Anesthesia, Local

Summary: the aim of our study is to examine the effect of bilateral infraorbital and infratrochlear nerve blocks for rhinoplasty operations on perioperative remifentanil need and postoperative pain scores.

rhinoplasty operations are one of the most applied cosmetic surgeries in the world. depending on the procedure type and hemodynamic lability, the quality of the surgical field, perioperative and postoperative complications as well as the success of surgery are affected.to provide improved surgical field quality, controlled hypotension and high concentrations of inhalation anesthetics, magnesium sulfate, remifentanil, clonidine, calcium channel blockers, tranexamic acid, intravenous nitroglycerin have been used. the american society of anesthesiology recommends using regional anesthesia methods and administering multimodal analgesia in every possible surgery. in our study we have performed bilaterral infraorbital an infratrochlear nerve blocks which are main nerves of the nose, for the patients of rhinoplasty. with blocking the infratrochlear and infraorbital nerves we will examine the need for remifentanil during surgery, postoperative pain scores.

Eligibility criteria:
inclusion criteria: patients undergoing rhinoplasty surgery exclusion criteria: * bleeding disorder * patient refusal * age under 18
amg 151 amgen protocol number 20100761

Conditions: Diabetes Mellitus

Summary: this is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. amg 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.


Eligibility criteria:
inclusion criteria: * age 18 to 75 years, inclusive * diagnosis of type 2 diabetes mellitus * hba1c levels 7.5% to 11.0%, inclusive, at screening * fasting c-peptide levels ≥ 0.2 nmol/l at screening * bmi ≥ 25 to \< 45 kg/m2 at screening * treated with metformin monotherapy for at least 3 months prior to randomization; the metformin dose must be ≥ 850 mg daily for at least 2 months immediately prior to randomization * if a subject is being treated for hyperlipidemia or hypertension they should be on stable medication for 30 days before randomization * subject has provided informed consent. exclusion criteria: * history of type 1 diabetes * history of significant weight gain or loss (\> 10%) during the 4 weeks before randomization * use of any weight loss medication (over the counter or prescription) within 60 days of randomization * use of any oral or injectable anti-hyperglycemic medication (other than metformin) within 3 months prior to randomization * use of chronic and/or continuous insulin administration for \> 15 days in an outpatient setting to achieve and maintain glycemic control prior to randomization * have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months * have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, or currently diagnosed as having hypoglycemia unawareness * evidence of active infections that can interfere with the study * presence of clinically significant organ system disease that is not stabilized or may interfere with the study * currently receiving immunosuppressive therapy * history of positive hiv, chronic hepatitis b or c, or cirrhosis * have symptomatic congestive heart failure or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure or stroke in the past 6 months prior to screening. * history of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, ph or absorption * any finding on the screening ecg that in the opinion of the investigator requires further cardiovascular evaluation * poorly controlled hypertension defined as diastolic pressure \> 100 mm hg or systolic pressure \> 160 mm hg (assessed on two separate occasions during the screening period) * malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if a malignancy occurred \> 5 years ago, subject is eligible with documentation of disease-free state since treatment) * use of known inhibitors or inducers of cyp3a4 are not permitted 30 days prior to randomization

Keywords: diabetes mellitus metformin
phrenic nerve stimulation for treatment of central sleep apnea

Conditions: Sleep Apnea, Central; Heart Failure

Summary: the study objectives are to demonstrate the ease and safety of bilateral cervically implanted phrenic nerve stimulators for central sleep apnea in patients with heart failure. to demonstrate the efficacy, both in the short and long term, of implanted phrenic nerve stimulators in patients with central sleep apnea and heart failure. central sleep apnea is a form of hypoventilation syndrome, for which this device is fda approved. we will also determine if the patient's quality and duration of life is improved by using the pns to treat csa in heart failure patients.

this is a multi-center prospective cohort study to monitor the effect of bilateral phrenic nerve stimulation for treatment of central sleep apnea (csa) in patients with heart failure. there will be 2 groups of study patients, both with csa and heart failure. one group will receive the phrenic nerve pacer, and one will not. both groups will have the same medical oversight, management, and assessment of heart health whether they receive the pacer or not. subjects will have a physical exam, review of medications, new york heart association (nyha) functional classification assessment for heart failure, minnesota living with heart failure (mlwhf) questionnaire for quality of live assessment and blood test for pro-bnp. in-lab sleep study will be required if subject haven't had one within 3 months, and echocardiogram, if subjects haven't had one within 30 days. if subjects are willing to have stimulator placement procedure, they'll have an ent consult. subjects in the procedure arm will have phrenic nerve stimulator placement procedure, and 3 weeks after procedure follow up visit with ent doctor to activate the device and have sleep study to confirm proper settings.

Eligibility criteria:
inclusion criteria: * 1. male or female, age 18 to 80 years inclusive. 2. new york heart association (nyha) class iii or iv, or nyha class ii with an episode of heart failure requiring hospitalization in the past 24 months. 3. stable on guide line directed medical therapy (gdmt) for 30 days prior to enrollment. 4. moderate or severe sleep apnea, that is an apnea hypopnea index (ahi) of \>15/hour with \>50% being central apneas. 5. willing and able to provide written informed consent in compliance with the regulatory requirements. if a subject is unable to provide written informed consent, written informed consent may be obtained from the subject's legal representative. exclusion criteria: 1. phrenic nerve palsy. 2. baseline hypoxia (oxygen saturation \<90% on room air). 3. on supplemental oxygen. 4. severe copd. 5. unstable angina, mi or cardiac procedure within 3 months of phrenic nerve stimulator placement. 6. unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol. 7. any other reasons that, in the opinion of the investigator, the candidate is determined to be unsuitable for entry into the study. -
text message appointment reminders

Conditions: Text Messages; Emergencies

Summary: this project proposes administer and evaluate via a randomized controlled trail a text message-based appointment reminder system to promote attendance at clinic appointments after ed discharge.

failure to attend scheduled clinic appointments causes inefficiency within the healthcare system, and frequently results in ed visits for non-emergent conditions such as medication refills, ambulatory care sensitive conditions which are potentially preventable with appropriate outpatient management (e.g. foot infections). many patients seen in the ed report they were unaware of past or future outpatient appointments for which they had been scheduled. these patients are clearly in need of primary care, yet fail to attend 30% of all scheduled outpatient appointments. patients most often report that they failed to attend scheduled appointments as a result of forgetfulness or confusion regarding dates, times, or locations. national data confirmed by our previous work in the lac+usc ed demonstrates that \> 80% of this population reports using a text-capable mobile device. the investigators believe a system of text message appointment reminders has tremendous potential to facilitate clinic attendance among these patients in desperate need of primary care.

Eligibility criteria:
inclusion criteria: * age \>18 * able to provide consent and read in english or spanish * have a text message capable mobile phone * know how to receive text messages * have upcoming scheduled clinic appointments exclusion criteria: * unable to provide written informed consent * incarcerated * critically ill * altered mental status

Keywords: text messaging clinic appointment attendance emergency department primary care
contribution of ondansetron to preventing post-dural puncture headaches following spinal anesthesia

Conditions: Post-Dural Puncture Headache

Summary: a prospective, bicentric, randomized, double-blind controlled study including parturients scheduled for elective caesarean delivery under spinal anaesthesia and randomized and assigned to one of the two groups: group o ondansetron : receiving intravenous (iv) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia group c control : receiving iv normal saline 5 ml (control group) 5 min before spinal anesthesia objective : to evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section.

spinal anesthesia is the most common anesthetic technique used for caesarean sections. however, it is not denied from complications. post-dural puncture headache is a major complication of spinal anesthesia, with an incidence ranging from 1.5% to 36%. objective : to evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section. the investigators conducted a prospective, bicentric, randomized, double-blind controlled study over a period of 07 months from november 2023 to june 2024. the investigators included in the study all parturients: * aged between 18-45 years * asa 2 * between 37 and 41 weeks of gestation * scheduled for elective caesarean delivery under spinal anaesthesia * to be delivered by unscheduled caesarean section whose indication does not involve a vital maternal or fetal emergency, according to the lucas' classification. the eligible parturients were randomly assigned to two groups through block randomization using computerized random numbers. were assigned to one of the two parallel groups to receive either : * intravenous (iv) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia : group o (ondansetron) * or iv normal saline 5 ml (control group) 5 min before spinal anesthesia : group c (control)

Eligibility criteria:
inclusion criteria: * aged between 18-45 years * asa 2 * between 37 and 41 weeks of gestation * scheduled for elective caesarean delivery under spinal anaesthesia * to be delivered by unscheduled caesarean section whose indication does not involve a vital maternal or fetal emergency, according to the lucas' classification exclusion criteria: * all patients who required : * more than two attempts for spinal anaesthesia * conversion to general anesthesia following failure of spinal anesthesia (defined as a sensory block level \<t6) or an intraoperative complication (such as hemorrhage or anaphylactic shock). as well as patients who have subsequently withdrawn their consent for participating to our study.
electroencephalographic characteristics of chronic pain in patients with spinal cord injury

Conditions: Chronic Pain

Summary: the diagnosis of chronic pain currently lacks objective and quantifiable biomarkers. this study aims to observe the eeg characteristics of patients with chronic pain following spinal cord injury and subsequently administer analgesic interventions with remifentanil, esketamine, flurbiprofen, and spinal cord stimulation. the correlation between eeg features and pain intensity will be examined. the research aims to advance the objectification of chronic pain diagnosis and treatment.


Eligibility criteria:
spinal cord injury patients with chronic pain inclusion criteria: * age 18 - 65 years old; * american society of anesthesiologists (asa) i-iii; * dextromanual; * chronic pain following spinal cord injury; * spinal cord electrical stimulator implantation under general anesthesia; * signed informed consent. exclusion criteria: * people with mental and behavioral disorders. * previous history of craniocerebral disease; * history of drug and alcohol abuse; * patients with aphasia or inability to cooperate with the pain assessments; * previous adverse reaction to esketamine, opioids or nsaids; * known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure); * patients with myasthenia gravis, bronchial asthma, or a predisposition to respiratory depression; * bleeding tendency; * bmi ≥ 35 kg/m²; * pregnancy or lactation. spinal cord injury patients without pain inclusion criteria: * age 18 - 65 years old; * american society of anesthesiologists (asa) i-iii; * dextromanual; * spinal cord injury patients without pain; * spinal cord electrical stimulator implantation under general anesthesia; * signed informed consent. exclusion criteria: * people with mental and behavioral disorders. * previous history of craniocerebral disease; * history of drug and alcohol abuse; * patients with aphasia or inability to cooperate with the pain assessments; * previous adverse reaction to esketamine, opioids or nsaids; * known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure); * patients with myasthenia gravis, bronchial asthma, or a predisposition to respiratory depression; * bleeding tendency; * bmi ≥ 35 kg/m²; * pregnancy or lactation.

Keywords: multichannel electroencephalogram patients with spinal cord injury esketamine remifentanil flurbiprofen spinal cord stimulation
imaging with [89zr]panitumumab-pet/mri in patients with newly diagnosed colorectal cancer

Conditions: Metastatic Colon Cancer

Summary: this clinical study will investigate the utility of pet imaging with \[89zr\]panitumumab for imaging of egfr expression in newly diagnosed colon cancer patients to assess lymph node involvement. if promising, this data will be used to design larger trials.


Eligibility criteria:
inclusion criteria: * be at least 19 years of age. * diagnosis of colon cancer * scheduled to undergo surgical resection exclusion criteria: * inability to provide informed consent * pregnancy * inability to lie still for the imaging study * weight over 350 lbs., due to the scanner bore size * contraindication for mri study (e.g. non-removable metal implants or certain tattoos) * inability to receive omnipaque (iohexol) iodinated contrast * inability to receive glucagon * inability to receive eovist (gadoxetate disodium) gadolinium based contrast agent * allergy to contrast imaging agents * finding or suspicion of distant metastases on ct
selective dentine removal in primary teeth

Conditions: Caries, Dental

Summary: background there is little information regarding the longevity of the restored tooth, considering the health of the pulp-dentine complex, in children who do not sufficiently cooperate with dental treatment. aim to evaluate the longevity of primary molar teeth with an occluso-proximal cavity that was treated with the selective removal of carious tissue. design a total of 150 children were allocated to two parallel groups: group 1 (g1, n = 70, control, ketac molar easymix®, 3m/espe, seefeld, ge) and group 2 (g2, n = 80, test, maxxion®, fgm, joinville, br). the study was double-blinded, and an operator specialized in paediatric dentistry performed the selective removal of soft dentine and the restoration of the cavity with gic. during the follow-up periods, the teeth were evaluated via periapical radiography by two trained examiners specialized in radiology. statistical analysis was performed using stata 11.2 software (statacorp, texas, usa) and a survival curve (kaplan-meier).


Eligibility criteria:
inclusion criteria: * an active denture caries lesion * the molars in primary, without anterior restoration, with the exclusive involvement of occlusal and mesial or distal surfaces present (international caries detection and evaluation system, icdas score 5) exclusion criteria: * those who did not accept care after 3 adaptation sessions * teeth with the following characteristics were excluded from the study: spontaneous pain, pressure sensitivity, suspected cellulose involvement, necrosis pulp, fistula, or tooth mobility * teeth in which extension of the lesion could lead to pulpal exposure were excluded * children whose parents or guardians do not sign an informed consent term

Keywords: minimally invasive dentistry dental caries dentine
female sexual dysfunction in renal failure

Conditions: Evaluations of Sexual Dysfunction of Female in Chronic Renal Failure

Summary: a myriad of sexual problems affect men and women with chronic kidney disease (ckd), including decreased libido, erectile dysfunction, dysmenorrhea, and infertility. menstrual abnormalities are common in ckd and many women are an-ovulatory . causes of sexual dysfunction in ckd include hormonal alterations along with vascular, neurologic, psychogenic, and other factors, such as medications, contribute to the development of sexual dysfunction . sexual dysfunction in females is mainly due to hormonal factors and manifests mainly as menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive.

hormonal changes in chronic kidney disease are seen in prolactine, gonadotropins, and gonadal hormones. in women with ckd, elevated levels of follicle-stimulating hormone (fsh) and luteinizing hormone (lh) are common. these hormonal changes are detected in the early stages of kidney disease and progressively worsen as kidney disease progresse . . women with chronic renal failure commonly have elevated circulating prolactin levels. as in men with chronic renal failure, the hypersecretion of prolactin in this setting appears to be autonomous, as it is resistant to maneuvers designed to stimulate or inhibit its release. it has been suggested that the elevated prolactin levels may impair hypothalamic-pituitary function and contribute to sexual dysfunction and galactorrhea in these patients. however, uremic women treated with bromocryptine rarely resume normal menses and continue to complain of galactorrhea (if present), despite normalization of the plasma prolactin concentration. thus, factors other than hyperprolactinemia must be important in this setting .

Eligibility criteria:
inclusion criteria: * -female patients with chronic renal failure (egfr \<15 ml/min/1.7m2 ) on dialysis or not. * age from 18 to 45 years old. * married. * sexually active during the last 6 monthes. exclusion criteria: * pregnant women. * other medical diseases ( diabetes mellitus ,cardiac disorders ,neurological disorders and other systematic diseases). * taking medications affect sexuality function e.g. antidepressant drugs.